ORIC Pharmaceuticals, Inc. ORIC NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score

59/100

3/6 Pass

SharesGrow Intrinsic Value

Income Statement Balance Sheet Cash Flow Statement

Annual Quarterly

ORIC Pharmaceuticals, Inc. (ORIC) generated $-113.37M in operating cash flow for fiscal year 2025. After capital expenditures of $712K, free cash flow was $-114.08M.

Cash conversion ratio was 0.88x, suggesting some earnings are non-cash.

Criteria supported by this page:

HEALTH (100/100, Pass) — demonstrate the company can comfortably service its debt
MOAT (40/100, Fail) — limited free cash flow weakens the competitive position
INCOME (?/100) — Cash conversion ratio was 0.88x suggests some earnings are non-cash items

Overall SharesGrow Score: 57/100 with 3/7 criteria passed.

SharesGrow 7-Criteria Score

59/100

SG Score

View full scorecard →

✓

VALUE

100/100

Price-to-Earnings & upside

→ Valuation

✓

FUTURE

100/100

Analyst consensus

→ Forecast

✗

PAST

0/100

→ Income

✓

HEALTH

100/100

Debt-to-Equity & liquidity

Proven by this page

✗

MOAT

40/100

Proven by this page

✗

GROWTH

15/100

→ Income

—

INCOME

N/A

No coverage

ORIC Pharmaceuticals, Inc. Cash Flow History

Metric	TTM	FY2025	FY2024	FY2023	FY2022
Operating Cash Flow	$-110.97M	$-113.37M	$-112.66M	$-85.69M	$-75.14M
Capital Expenditure	$-485K	$-712K	$0.00	$-849K	$-2.08M
Free Cash Flow	$-111.46M	$-114.08M	$-113.85M	$-86.54M	$-77.22M